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Results: For all patients, the treatment was tolerated well. 
In some patients, a lower dose to the PTV was given in order 
to protect the organs at risk. This was especially the case in 
patients that received a second salvage treatment. No 
patients developed a new grade 3 (or more) toxicity. One 
patient developed an acute urinary retention after primary 
focal HDR brachytherapy. Other grade 2 toxicity was 
uncommon in patients that received HDR brachytherapy as a 
primary treatment. In patients with a salvage treatment, 
grade 2 toxicity such as urinary infections and incontinence 
occurred in 3 of 8 patients. The 3 patients that received a 
second salvage treatment had not developed severe toxicity. 
However, follow up of these patients is very short (1-6 
months). 
 
Conclusion: Focal HDR brachytherapy as focal, salvage and 
secondary salvage treatment seems clinically feasible and 
safe. It could be a promising treatment modality to reduce 
severe side effect in patients with primary prostate cancer. 
Furthermore, it could postpone hormonal treatment in 
patients with recurrent or secondary recurrent prostate 
cancer. 
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In this contribution the physical properties of protons and 
other Ions will be outlined and the differences between 
different ions will be highlighted. The relevance of these 
properties with respect to radiotherapy will be discussed. In 
detail the physical properties to be discussed are the depth 
dose distribution, lateral scattering and energy loss 
straggling. These quantities will mainly affect the dose 
conformation potential of the various ion beams through the 
distal and lateral penumbra and the dose in the entrance 
region. The most important difference here arises through 
the multiple small angle scattering of particles which is 
strongly depend on the mass of the Ions: for heavier Ions, the 
lateral penumbra will be significantly smaller than for 
protons.  
Another very important physical paramter is the stopping 
power of the particles, as this quantity will influence the 
radiobiological properties of the differnt ions. The stopping 
power describes the energy loss of a particle per pathlength 
and be accuaretly calculated using the Bethe formalism. 
More important for the radiobiological effects is the linear 
energy transfer (LET), which is often used synomyously to 
stopping power. LET describes the eneryg transferred into a 
narrow region around the primary ion track and can also be 
calculated using the Bethe formalism. While the LET of a 
pure beam of ions with a fixed energy is well defined, the 
LET of a mixed radiation field is more complex. The reason 
for that is, that in a mixed radiation field, LET has to be 
averaged over the different Ions contributing. This is often 
done by using the so-called "dose averaged LET", where the 
LET of each particle is weighted according to the dose it is 
contributing. Another way of defining an average LET is by 
averaging over the fluence (or alternatively over the track 
length). Both average LET definitions are being used for 
various biological applications and will be presented. When 
discussing the relative biological effectiveness (RBE) of ion 
beams, one has to be aware of this difference.  
Finally the nuclear fragmentation of ions may lead to strong 
differences in the spectrum, or mixture of ions of different 
kind at different points in depth. The relevance of these 
nuclear fargments becomes clear, when comparing the dose 
just behind the Bragg peak of a primary carbon ion beam 
(which is completely due to light fragments) and a proton 
beam (which is completely due to protons). An overview of 
the characteristics of the fragmentation spectra of Ions will 
therefore also be given. 
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Both, carbon ions and protons show an inverted depth dose 
profile (Bragg-peak) and allow for highly conformal 
irradiations of tumors in the neighborhood of radiosensitive 
normal tissues. Heavier ions such as carbon ions additionally 
show an increased linear energy transfer (LET) towards the 
distal edge of the Bragg-peak leading to an increased relative 
biological effectiveness (RBE) with respect to photon 
irradiations [1]. While the RBE for clinical proton beams is 
currently fixed to 1.1, the RBE of carbon ion varies 
significantly within the treatment field and has to be 
calculated by RBE-models. The RBE-models, however, 
introduce additional uncertainties, which have to be 
considered in treatment planning and especially in clinical 
dose prescription. 
As protons and carbon ions exhibit almost comparable 
geometrical accuracy, the clinical question whether protons 
or carbon will be more beneficial for the patient mainly 
addresses the independent role of the high-LET effect in 
radiotherapy. The answer to this question is related to the 
following subquestions: (i) How accurate is the applied RBE-
model? (ii) Is a fixed proton RBE of 1.1 accurate enough for 
all field configurations? (iii) Which tumor types are best 
suited for heavy ions? (iv) Can high-LET irradiations overcome 
radioresistance of hypoxic tumors? 
While questions (i) and (ii) refer to normal tissue reactions, 
(iii) and (iv) address the impact of tumor-specific resistance 
factors on the radiation response. An additional benefit of 
heavy ions will strongly depend on the differential response 
between tumor and normal tissue. Although the final prove or 
disprove of advantages has to be provided by prospectively 
randomized clinical trials, ongoing preclinical experiments 
can help to study the subquestions (i)-(iv) separately, i.e. to 
benchmark RBE-models (e.g. LEM I vs IV), to select suitable 
tumor entities, to setup clinical trials and to generally 
improve the understanding of normal and tumor tissue 
response after high- vs. low-LET irradiation. 
The presentation will give an introduction on the concepts 
describing the response to high-LET irradiations and will give 
an overview on the available in vivo data with focus on the 
current answers to the above questions. 
References 
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Particle therapy has been available in hospital setting since 
1991. About 100.000 Patients have been treated worldwide 
with protontherapy and more than 10.000 patients have been 
treated with carbon ion radiotherapy. After almost 15 years 
in which this modality was available only in few centres in 
the last ten years the number of new particle facilities has 
steeply increased in the US and in Asia and more recently 
several facilities have been planned in Europe. Protontherapy 
has traditionally been used because of its strong preclinical 
rationale based on its favourable physical properties that 
allow a substantial reduction in integral dose and exposure of 
non-target tissues. Carbon ion radiotherapy has mainly been 
used for its radiobiological property that may offer an 
advantage in the treatment of macroscopic tumours made of 
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an heterogeneous cell population with a radio-resistant 
compartment. Evidence to support the use of particle 
therapy evolved in the past 25 years from level III (preclinical 
rationale) to level II (prospective non randomized trials). A 
hot debate has been on-going in the scientific community 
about the need of prospective RCT testing head to head 
particles versus modern X-ray radiotherapy. Those against 
the need of RCT argued that dose distribution was such a 
strong surrogate endpoint that RCT were not needed and that 
dose distribution had always guided the evolution of 
radiotherapy without the need of RCT. Those in favour 
argued that the only relevant endpoints were clinical 
outcome and measurable toxicity and that dose distributions 
of protontherapy despite its unquestionable advantage in 
terms of integral dose may be in some case less favourable 
than advanced x-ray dose distribution because of lateral 
scattering and shallower dose gradients in the high dose 
region. Historically only a single RCT of particle versus 
photons has been conducted, namely the UCSF-LBNL trial 
comparing helium ions radiotherapy versus Iodine-125 plaque 
brachytherapy for choroidal and ciliary body melanoma . 
Long terms result of the trial a showed a clear advantage of 
charged particles over brachytherapy in terms of local 
control. However this result did not definitively solve the 
issue as helium is no longer used in clinical practice and 
extrapolation of this trial to protontherapy is maybe not 
straightforward; moreover the trial was criticized because of 
a supposed suboptimal technique in the brachytherapy arm. 
With the increased availability of proton facilities the amount 
of non-randomized evidence is rapidly increasing and several 
prospective non-randomized trial are being conducted. At 
present particle therapy has found its way in several 
guidelines. As an example in the last version of ESMO 
guidelines for bone sarcoma particle therapy is considered 
the first option for chordoma both in the post operative 
setting and for inoperable disease. In this framework also 
RCT are at present being conducted. A prospective phase II 
RCT in stage II-IIB NSCLC patients (NCT00915005) randomized 
to either photons or protons adaptive IGRT with two levels of 
dose (66 Gy [RBE] + vs. 74 Gy [RBE]) with primary endpoints 
local control and toxicity G≥3 has completed its accrual. Two 
other trials are testing protontherapy vs photons X-Ray in 
locally advanced NSCLC (RTOG 1308) or in centrally located 
stage I NSCLC (NCT01511081) and are expected to complete 
accrual in 2020 and 2016. Another prospective phase III RCT 
ongoing at MGH testing IMRT vs protontherapy for prostate 
cancer (NCT01617161) is expected to complete accrual in 
2016 A prospective phase II/III RCT for stage III and IV 
oropharyngeal SCC (NCT01893307) is comparing 70 Gy [RBE] 
delivered with either IMRT or intensity modulated 
protontherapy. And is expected to complete accrual by 2023 
Another trial is testing protons vs photons in GBM 
(NCT01854554) and should complete accrual by 2017. A RCT 
is recruiting patient with oesophageal cancer to test chemo 
radiation with photons vs. chemo radiation with protons 
(NCT01512589) and should be completed within 2018. Other 
RCT are ongoing comparing protons versus carbon ions in 
sacral chordoma (ISAC trial NCT01811394) in skull base 
chordoma (NCT01182779) and in skull base chondrosarcoma 
(NCT01182753). RCT are recruiting patient to test 
protontherapy vs RF ablation in HCC (NCT01963429) or 
protontherapy + sorafenib vs. sorafenib alone in HCC 
(NCT01141478). A RCT of particle therapy vs surgery for 
sacral chordoma (SACRO) is in its final design stage in Europe. 
Another phase III RCT of carbon ion radiotherapy versus 
photons or protons radiotherapy for head and neck soft tissue 
sarcoma and adenoid cystic carcinoma (PHRC ETOILE-ULICE) 
is going to start recruitment in the next year. In conclusion 
the present day clinical evidence for particle therapy is of 
level II (with the only exception of eye melanoma). A large 
effort to produce level I evidence is ongoing worldwide. 
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Purpose or Objective: This study evaluates 
FTY720/Fingolimod as a potential mitigator of radiation-
induced neurocognitive dysfunction. 
 
Material and Methods: The effects of radiation and FTY720 
on neural progenitor cells (NPCs) and brain tumor stem cells 
(BTSCs) were tested in vitro. To study radiation-induced 
neurocognitive deficits, 6 week-old C57/Bl/6J mice received 
0 or 7 Gy cranial irradiation and were treated with 
intraperitoneal FTY720 or vehicle for seven weeks. Fear 
conditioning and the Morris water maze were then employed 
to test learning and memory. Immunohistochemical staining 
for NPCs and mature neurons was used to assess changes in 
neurogenesis. To test effects on tumor growth, mice 
harboring BTSC xenografts were treated with intraperitoneal 
FTY720 or vehicle for six weeks. 
 
Results: In NPCs, FTY720 induced ERK1/2 phosphorylation in 
the presence of radiation. In glioma cells, ERK1/2 
phosphorylation was detected at baseline, and FTY720 did 
not elicit any further increase. Correspondingly, FTY720 
increased the viability of NSCs but not glioma cells after 
radiation. Inhibiting S1P1/MAPK signaling in NPCs abolished 
the protective effects of FTY720. In irradiated mice, learning 
deficits were manifested by significantly longer latency times 
compared to non-irradiated controls (p = 0.001). The deficits 
were fully restored by FTY720. In irradiated brains, FTY720 
maintained a viable NPC pool and restored the 
cytoarchitecture of the DG granular cell layer. In mice 
harboring BTSC xenografts FTY720 delayed tumor growth and 
improved survival (p=0.012). 
 
Conclusion: FTY720 mitigates radiation-induced learning 
dysfunction by partially restoring DG neurogenesis. 
Furthermore, FTY720 appears to delay tumor growth and 
improve survival in a xenograft glioma mouse model.  
 
OC-0045  
Dual pathway inhibition attenuates radiation-induced 
pulmonary inflammation and fibrosis 
N.H. Nicolay
1Heidelberg University Hospital, Radiation Oncology, 
Heidelberg, Germany 
1,2, M. Dadrich2,3, R. Lopez Perez2, U. Wirkner2, 
P. Peschke2, J. Debus1,2, P.E. Huber1,2 
2German Cancer Research Center, Radiation Oncology, 
Heidelberg, Germany 
3Frankfurt University Hospital, Radiology, Heidelberg, 
Germany 
 
Purpose or Objective: Radiation therapy is a mainstay for 
lung cancer therapy, but the effective dose is commonly 
limited by the onset of radiation-induced lung damage. Single 
pathway inhibitors against transforming growth factor β 
(TGFβ), platelet-derived growth factor (PDGF) and others 
have been shown in experimental models to attenuate 
radiation-induced pulmonary injury. However, the effects of 
multiple pathway inhibition regarding the development of 
these diseases remain unknown. 
 
Material and Methods: C57BL/6 mice were treated with a 
single dose of up to 20 Gy photons to their thoraxt o induce 
radiation induced lung toxicity. After Irradiation , small 
